Study finds differences in two AIDS treatments
A new study vice-chaired by Dartmouth-Hitchcock Medical Center pediatrician Paul Palumbo may cause changes to standard AIDS treatment strategies around the world. Palumbo presented the International Maternal Pediatric Adolescent AIDS Clinical Trials group study which demonstrated that an alternative AIDS treatment administered to children of HIV-positive mothers was significantly more effective than the most common treatment at the Conference on Retroviruses and Opportunistic Infections in Boston last week, Palumbo said in an interview with The Dartmouth. The study, known as "P1060" compared the effectiveness of two anti-retroviral drugs, Nevirapine and Kaletra, in treating HIV-positive children between the ages of six months and three years, according to Palumbo. The first phase of the study compared the effectiveness of Nevirapine and Kaletra in children who had previously taken Nevirapine and whose mothers had also taken Nevirapine during labor to reduce the risk of HIV transmission from mother to child, according to a Dartmouth Medical School press release.
